OncoMatch/Clinical Trials/NCT07783100
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Is NCT07783100 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies venetoclax, chidamide, and chiglitazar sodium (VCC) for relapsed or refractory acute myeloid leukemia.
Treatment: venetoclax, chidamide, and chiglitazar sodium (VCC) — To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Refractory AML, defined as failure to achieve remission after at least one prior treatment
Cannot have received: solid organ transplantation
Exception: prior stem cell transplantation (SCT) is permitted
Previous solid organ transplantation. Prior stem cell transplantation (SCT) is permitted; however, patients with graft-versus-host disease (GVHD) or those receiving ongoing immunosuppressive or GVHD-directed therapy are not eligible.
Lab requirements
Kidney function
Estimated creatinine clearance ≥50 mL/min
Liver function
AST and ALT ≤3.0 × ULN, unless attributable to leukemic organ involvement; total bilirubin ≤3.0 × ULN, unless attributable to leukemic organ involvement
Cardiac function
Clinically significant cardiovascular disease, including QTc >450 ms in males or >470 ms in females, ventricular tachycardia, second-degree atrioventricular block, myocardial infarction within 1 year, congestive heart failure, coronary artery disease requiring medical treatment [excluded]
Estimated creatinine clearance ≥50 mL/min. AST and ALT ≤3.0 × ULN, unless attributable to leukemic organ involvement; total bilirubin ≤3.0 × ULN, unless attributable to leukemic organ involvement. Clinically significant cardiovascular disease, including any of the following: Clinically significant QTc prolongation (QTc >450 ms in males or >470 ms in females); Ventricular tachycardia; Second-degree atrioventricular block; Myocardial infarction within 1 year prior to enrollment; Congestive heart failure; Coronary artery disease requiring medical treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07783100 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages